CA2835438A1 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents
Pirfenidone and anti-fibrotic therapy in selected patients Download PDFInfo
- Publication number
- CA2835438A1 CA2835438A1 CA2835438A CA2835438A CA2835438A1 CA 2835438 A1 CA2835438 A1 CA 2835438A1 CA 2835438 A CA2835438 A CA 2835438A CA 2835438 A CA2835438 A CA 2835438A CA 2835438 A1 CA2835438 A1 CA 2835438A1
- Authority
- CA
- Canada
- Prior art keywords
- pirfenidone
- receptor
- inhibitor
- agent
- fvc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489936P | 2011-05-25 | 2011-05-25 | |
| US61/489,936 | 2011-05-25 | ||
| US201161490057P | 2011-05-26 | 2011-05-26 | |
| US61/490,057 | 2011-05-26 | ||
| US201161523047P | 2011-08-12 | 2011-08-12 | |
| US61/523,047 | 2011-08-12 | ||
| US201161524961P | 2011-08-18 | 2011-08-18 | |
| US61/524,961 | 2011-08-18 | ||
| PCT/US2012/039538 WO2012162592A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2835438A1 true CA2835438A1 (en) | 2012-11-29 |
Family
ID=47217770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2835438A Abandoned CA2835438A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150164874A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2713732A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6170040B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140022048A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012258575B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835438A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1197159A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL229226A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013013752A (cg-RX-API-DMAC7.html) |
| SG (1) | SG195110A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012162592A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| BR112013022766A2 (pt) * | 2011-03-08 | 2016-12-06 | Auspex Pharmaceuticals Inc | método de administração de d-pirfenidona e kit |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| EP3194446B1 (en) * | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| DK3050574T3 (da) * | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
| US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| SG11201907673YA (en) * | 2017-03-13 | 2019-09-27 | Genfit | Pharmaceutical compositions for combination therapy |
| US20210363259A1 (en) * | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| CA3140129A1 (en) * | 2019-05-17 | 2020-11-26 | The Regents Of The University Of California | Mps modified peptides and use thereof |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
| EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| US20230129866A1 (en) * | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN114617890A (zh) * | 2020-12-08 | 2022-06-14 | 四川夏派森医药科技有限公司 | DH404在治疗SARS-CoV-2感染中的应用 |
| CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
| WO2023192646A1 (en) * | 2022-03-31 | 2023-10-05 | Puretech Lyt 100, Inc. | Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| CN1307997C (zh) * | 2002-06-28 | 2007-04-04 | 图兰恩教育基金管理人 | 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺 |
| WO2004103296A2 (en) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| WO2007119214A2 (en) * | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| HUE052220T2 (hu) * | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| AU2008265595B2 (en) * | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| EP2389227A4 (en) * | 2009-01-26 | 2012-08-08 | Intermune Inc | METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2012
- 2012-05-25 AU AU2012258575A patent/AU2012258575B2/en not_active Ceased
- 2012-05-25 KR KR1020137028921A patent/KR20140022048A/ko not_active Ceased
- 2012-05-25 MX MX2013013752A patent/MX2013013752A/es not_active Application Discontinuation
- 2012-05-25 JP JP2014512134A patent/JP6170040B2/ja not_active Expired - Fee Related
- 2012-05-25 SG SG2013086541A patent/SG195110A1/en unknown
- 2012-05-25 HK HK14109929.1A patent/HK1197159A1/xx unknown
- 2012-05-25 EP EP12788732.1A patent/EP2713732A4/en not_active Withdrawn
- 2012-05-25 WO PCT/US2012/039538 patent/WO2012162592A1/en not_active Ceased
- 2012-05-25 US US14/373,276 patent/US20150164874A1/en not_active Abandoned
- 2012-05-25 CA CA2835438A patent/CA2835438A1/en not_active Abandoned
-
2013
- 2013-11-04 IL IL229226A patent/IL229226A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ617415A (en) | 2017-07-28 |
| US20150164874A1 (en) | 2015-06-18 |
| EP2713732A1 (en) | 2014-04-09 |
| JP6170040B2 (ja) | 2017-07-26 |
| WO2012162592A1 (en) | 2012-11-29 |
| JP2014518880A (ja) | 2014-08-07 |
| KR20140022048A (ko) | 2014-02-21 |
| HK1197159A1 (en) | 2015-01-09 |
| SG195110A1 (en) | 2013-12-30 |
| EP2713732A4 (en) | 2014-12-03 |
| AU2012258575A1 (en) | 2013-11-21 |
| AU2012258575B2 (en) | 2017-03-02 |
| IL229226A0 (en) | 2014-01-30 |
| MX2013013752A (es) | 2014-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150164874A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| EP2285366B1 (fr) | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules | |
| US20240269126A1 (en) | Combination therapy for treatment of cancer | |
| CN115297862A (zh) | 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合 | |
| JP2021185144A (ja) | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 | |
| CN102908347A (zh) | 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 | |
| JP2014518880A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504611A (ja) | 組合せ医薬 | |
| US20220251105A1 (en) | Methods of treating a mk2-mediated disorder | |
| KR20180125966A (ko) | 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 | |
| JP2012515737A (ja) | メトトレキサートおよびdhodh阻害剤を含む組合せ剤 | |
| TW201841637A (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
| JP2019525948A5 (cg-RX-API-DMAC7.html) | ||
| TW202615042A (zh) | 用於治療進行性纖維化間質性肺病之新穎治療組合 | |
| JP2023531863A (ja) | 肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン(nk)-1受容体拮抗薬 | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| JP2012526772A (ja) | ホスホイノシチド3−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤 | |
| WO2019053595A1 (en) | INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA | |
| US20210353648A1 (en) | Grapiprant unit dosage forms | |
| JP2026082828A (ja) | レボケトコナゾールによる疾患の処置方法 | |
| JP2023512025A (ja) | 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 | |
| JP2007519646A (ja) | 体重の持続的低減のための化合物 | |
| JP7565132B2 (ja) | がんの治療又は予防用医薬 | |
| JP2023504115A (ja) | 肺動脈性肺高血圧症の治療方法 | |
| KR20200067859A (ko) | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170524 |
|
| FZDE | Discontinued |
Effective date: 20191024 |